Advent Venture Partners announces the appointment of Dr Richard Mason to the Life Sciences team as Executive-in-Residence


London, 1 May 2007 - Advent Venture Partners (“Advent Ventures”) today announces the appointment of Dr Richard Mason as Executive-in-Residence.  Richard will provide expertise, experience and leadership skills to key companies in the Advent Ventures portfolio.




Richard joins Advent Ventures from Cambridge Antibody Technology plc (‘CAT’) where he was Senior Vice President, Business Development and Commercial Operations.  During his time at CAT, Richard led multiple transactions, including the negotiation of CAT’s joint antibody discovery and development collaboration with AstraZeneca. Since 2005, he also chaired the R&D team responsible for CAT’s establishment of a therapeutic focus in oncology and the subsequent in-licensing of a number of antibody product candidates.




Prior to joining CAT, Richard co-founded the e-health company, Cambridge Health Informatics Limited, having previously gained an MBA from the University of Cambridge. Richard graduated in Medicine from the Medical School of St Bartholomew's Hospital and also holds a degree in Immunology from University College London. He is a qualified physician and before entering the business world he worked for 5 years for the NHS in internal medicine.




Commenting on this appointment, Dr Raj Parekh, Advent Ventures General Partner, said “We are delighted to have Richard join the team as part of our plan to add resources and skills to help our portfolio companies succeed.  His outstanding track record in business development will be a major asset for many of our portfolio companies”




For more information please contact:




Dr Raj Parekh/Dr Richard Mason, Advent Venture Partners, 020 7932 2100



Shona Prendergast / Francesca Reville,

Penrose Financial, 020 7786 4884 / 4811






About Advent Venture Partners – Advent Ventures is one of the most experienced technology venture capital firms in the UK. Established in 1981 it invests in both the Life Science and the Technology sectors.  Advent Ventures has over £500 million (US$ 900m) under management from institutional investors across Europe and the USA. It has backed around 60 life science companies of which, to date, 21 have obtained public listings and a further 9 companies have been sold including PowderMed (to Pfizer) and KuDOS Pharmaceuticals (to AstraZeneca). Recent investments by the Advent Life Sciences team include Norwegian radiopharmaceuticals company, Algeta; the US speciality pharma company, CardioKine Inc; the US medical device company NeoGuide, UK-based Thiakis which develops hormone-based treatments for obesity, the Swiss therapeutic antibody company, 4-Antibody and EUSA Pharma Inc, a new transatlanticspecialtypharmaceutical company.